Nymox Pharmaceutical sets Aug. 28 board election meeting

Nymox Pharmaceutical Corporation, a foreign private issuer, reports that it will hold a Special Shareholder's Meeting on August 28, 2026 to elect the members of its Board of Directors.

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation, a foreign private issuer, reports that it will hold a Special Shareholder's Meeting on August 28, 2026 to elect the members of its Board of Directors. A Notice of Meeting and a Management Proxy Circular accompany this announcement.

The company also states that its annual report on Form 20-F for the financial year ended December 31, 2025 has been delayed mainly due to previously reported changes in management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission. Nymox points to its website, www.nymox.com, for current 2026 updates.

Positive

• None.

Negative

• Form 20-F for 2025 delayed due to previously reported management and board changes.

Key Figures

Special shareholder meeting date: August 28, 2026 Financial year-end: December 31, 2025 Report month: August 2026

3 metrics

Special shareholder meeting date August 28, 2026 Date set for meeting to elect Board of Directors

Financial year-end December 31, 2025 Year covered by delayed Form 20-F annual report

Report month August 2026 Month referenced in the Form 6-K report of foreign private issuer

Key Terms

Special Shareholder's Meeting, Management Proxy Circular, Form 20-F, foreign private issuer

4 terms

Special Shareholder's Meeting financial

"will hold a Special Shareholder's Meeting August 28, 2026"

Management Proxy Circular financial

"see attachments for copies of the Management Proxy Circular"

A management proxy circular is a detailed briefing packet mailed or posted to shareholders before a company meeting that asks them to vote on key matters. It lays out agenda items, background information, management’s recommendations, pay and board candidate details, and instructions for authorizing someone to vote on your behalf. Investors use it like an agenda plus briefing notes to decide how votes could affect who controls the company, its strategy and future returns.

Form 20-F regulatory

"annual report on Form 20-F for the financial year ended"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Nymox Pharmaceutical (NYMXF) special shareholder meeting?

Nymox Pharmaceutical will hold a Special Shareholder's Meeting on August 28, 2026 to elect the members of its Board of Directors. Notice of Meeting and a Management Proxy Circular have been prepared for shareholders.

When will Nymox Pharmaceutical (NYMXF) hold its special shareholder meeting?

Nymox Pharmaceutical has scheduled a Special Shareholder's Meeting for August 28, 2026. The meeting is being called specifically for the election of the company’s Board of Directors, with details provided in the accompanying meeting notice and proxy circular.

What is the status of Nymox Pharmaceutical (NYMXF) Form 20-F annual report?

Nymox states that its Form 20-F annual report for the financial year ended December 31, 2025 has been delayed, mainly because of previously reported changes in management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission.

Why was Nymox Pharmaceutical (NYMXF) Form 20-F filing delayed?

The company explains that its annual report on Form 20-F for the year ended December 31, 2025 was delayed mainly due to previously reported changes in management and the Board, and it indicates that this report is planned to be filed with the SEC.

Where can Nymox Pharmaceutical (NYMXF) investors find 2026 updates and meeting materials?

Nymox directs investors to its website, www.nymox.com, for current 2026 updates. The company also provides a Notice of Meeting and a Management Proxy Circular as exhibits related to the August 28, 2026 special shareholder meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 03:38 PM Accepted by SEC EDGAR 08/07/2026 - 03:38 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August, 2026

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Nymox (“the Company”) will hold a Special Shareholder's Meeting August 28, 2026 for the election of the Company's Board of Directors ("the Board").  Please see attachments for copies of the Management Proxy Circular and related materials. Nymox annual report on Form 20-F for the financial year ended December 31, 2025,  has been delayed mainly due to previously reported changes in Management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission ("SEC"). The Company's website with current 2026 updates is www.nymox.com

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Notice of Meeting
99.2		Management Proxy Circular

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 7, 2026

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

4

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 NOTICE OF MEETING 3.0 KB
• EX-99.2 MANAGEMENT PROXY CIRCULAR 23.4 KB